is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112. 

Current Cases

Nymox Pharmaceutical Corporation [NASDAQ: NYMX]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Nymox Pharmaceutical Corporation

 

Oklahoma City, OK (December 1, 2014) – On November 24, 2014, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Nymox Pharmaceutical Corporation (NASDAQ: NYMX).  The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is January 31, 2011 through November 2, 2014.  More specifically, this litigation was filed because the Defendants failed to disclose material information affecting the Phase 3 clinical trials for the Company’s proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH).  NX-1207 showed positive results for the treatment of BPH in Phase 1 and Phase 2 clinical trials in the U.S. The Company regularly provided positive updates on the Phase 3 clinical trials. However, on November 2, 2014 the Defendants disclosed that the two Phase 3 U.S. studies of NX-1207 was halted because the drug failed to meet its primary endpoints for efficacy.  Defendants held a conference call on November 3, 2014 with analysts to explain the failure and on that call disclosed to the market for the first time, among other things, the difficulties they faced in enrolling men for the trials and the subjective nature of the measurement of the drug's success. On this news, the Company’s common stock declined to close on November 3, 2014 at $0.93 per share.

 

Plaintiff seeks to recover damages on behalf of all Nymox Pharmaceutical Corporation shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above.  You may move the Court no later than Monday, January 26, 2015 to serve as a lead plaintiff for the entire Class.  However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification.  Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN:  Robin.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.